Literature DB >> 28701398

Protection against HIV Acquisition in the RV144 Trial.

Ronald C Desrosiers1.   

Abstract

Differences of opinion regarding whether there may, or may not, have been protective efficacy in the RV144 vaccine trial have important societal implications.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  HIV vaccine; efficacy trials

Mesh：

Substances：

Year:  2017        PMID： 28701398      PMCID： PMC5571267          DOI： 10.1128/JVI.00905-17

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  7 in total

1.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

2.  Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trials.

Authors:  Peter B Gilbert; James O Berger; Donald Stablein; Stephen Becker; Max Essex; Scott M Hammer; Jerome H Kim; Victor G Degruttola
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

3.  Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Authors:  Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert
Journal:  N Engl J Med       Date:  2013-10-07       Impact factor: 91.245

4.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

Review 5.  Immune correlates of vaccine protection against HIV-1 acquisition.

Authors:  Lawrence Corey; Peter B Gilbert; Georgia D Tomaras; Barton F Haynes; Giuseppe Pantaleo; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2015-10-21       Impact factor: 17.956

6.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

7.  Comprehensive sieve analysis of breakthrough HIV-1 sequences in the RV144 vaccine efficacy trial.

Authors:  Paul T Edlefsen; Morgane Rolland; Tomer Hertz; Sodsai Tovanabutra; Andrew J Gartland; Allan C deCamp; Craig A Magaret; Hasan Ahmed; Raphael Gottardo; Michal Juraska; Connor McCoy; Brendan B Larsen; Eric Sanders-Buell; Chris Carrico; Sergey Menis; Gustavo H Kijak; Meera Bose; Miguel A Arroyo; Robert J O'Connell; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Supachai Rerks-Ngarm; Merlin L Robb; Tatsiana Kirys; Ivelin S Georgiev; Peter D Kwong; Konrad Scheffler; Sergei L Kosakovsky Pond; Jonathan M Carlson; Nelson L Michael; William R Schief; James I Mullins; Jerome H Kim; Peter B Gilbert
Journal:  PLoS Comput Biol       Date:  2015-02-03       Impact factor: 4.475
  7 in total
  14 in total

1.  Revisiting the Correlate of Reduced HIV Infection Risk in the Rv144 Vaccine Trial.

Authors:  Susan Zolla-Pazner; Peter B Gilbert
Journal:  J Virol       Date:  2019-08-13       Impact factor: 5.103

2.  HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions.

Authors:  David Easterhoff; Justin Pollara; Kan Luo; Benjamin Janus; Neelakshi Gohain; LaTonya D Williams; Matthew Zirui Tay; Anthony Monroe; Kristina Peachman; Misook Choe; Susie Min; Paolo Lusso; Peng Zhang; Eden P Go; Heather Desaire; Mattia Bonsignori; Kwan-Ki Hwang; Charles Beck; Matina Kakalis; Robert J O'Connell; Sandhya Vasan; Jerome H Kim; Nelson L Michael; Jean-Louis Excler; Merlin L Robb; Supachai Rerks-Ngarm; Jaranit Kaewkungwal; Punnee Pitisuttithum; Sorachai Nitayaphan; Faruk Sinangil; James Tartaglia; Sanjay Phogat; Kevin Wiehe; Kevin O Saunders; David C Montefiori; Georgia D Tomaras; M Anthony Moody; James Arthos; Mangala Rao; M Gordon Joyce; Gilad Ofek; Guido Ferrari; Barton F Haynes
Journal:  JCI Insight       Date:  2020-01-30

3.  Clade C HIV-1 Envelope Vaccination Regimens Differ in Their Ability To Elicit Antibodies with Moderate Neutralization Breadth against Genetically Diverse Tier 2 HIV-1 Envelope Variants.

Authors:  Samantha Burton; Lori M Spicer; Tysheena P Charles; Sailaja Gangadhara; Pradeep B J Reddy; Tiffany M Styles; Vijayakumar Velu; Sudhir Pai Kasturi; Traci Legere; Eric Hunter; Bali Pulendran; Rama Amara; Peter Hraber; Cynthia A Derdeyn
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

4.  Mamu-B*17+ Rhesus Macaques Vaccinated with env, vif, and nef Manifest Early Control of SIVmac239 Replication.

Authors:  Mauricio A Martins; Damien C Tully; Núria Pedreño-Lopez; Benjamin von Bredow; Matthias G Pauthner; Young C Shin; Maoli Yuan; Noemia S Lima; David J Bean; Lucas Gonzalez-Nieto; Aline Domingues; Martin J Gutman; Helen S Maxwell; Diogo M Magnani; Michael J Ricciardi; Varian K Bailey; John D Altman; Dennis R Burton; Keisuke Ejima; David B Allison; David T Evans; Eva G Rakasz; Christopher L Parks; Myrna C Bonaldo; Saverio Capuano; Jeffrey D Lifson; Ronald C Desrosiers; Todd M Allen; David I Watkins
Journal:  J Virol       Date:  2018-07-31       Impact factor: 5.103

5.  Testing a global null hypothesis using ensemble machine learning methods.

Authors:  Sunwoo Han; Youyi Fong; Ying Huang
Journal:  Stat Med       Date:  2022-03-07       Impact factor: 2.497

6.  A new cell line for assessing HIV-1 antibody dependent cellular cytotoxicity against a broad range of variants.

Authors:  Allison S Thomas; Melissa Ghulam-Smith; Alex Olson; Carolyn Coote; Oscar Gonzales; Manish Sagar
Journal:  J Immunol Methods       Date:  2020-03-02       Impact factor: 2.287

Review 7.  Vaccine-induced V1V2-specific antibodies control and or protect against infection with HIV, SIV and SHIV.

Authors:  Susan Zolla-Pazner; Raymond Alvarez; Xiang-Peng Kong; Svenja Weiss
Journal:  Curr Opin HIV AIDS       Date:  2019-07       Impact factor: 4.283

Review 8.  V2-Specific Antibodies in HIV-1 Vaccine Research and Natural Infection: Controllers or Surrogate Markers.

Authors:  Ralf Duerr; Miroslaw K Gorny
Journal:  Vaccines (Basel)       Date:  2019-08-06

9.  Vaccine protection against rectal acquisition of SIVmac239 in rhesus macaques.

Authors:  Lucas Gonzalez-Nieto; Isabelle M Castro; Georg F Bischof; Young C Shin; Michael J Ricciardi; Varian K Bailey; Christine M Dang; Nuria Pedreño-Lopez; Diogo M Magnani; Keisuke Ejima; David B Allison; Hwi Min Gil; David T Evans; Eva G Rakasz; Jeffrey D Lifson; Ronald C Desrosiers; Mauricio A Martins
Journal:  PLoS Pathog       Date:  2019-09-30       Impact factor: 6.823

10.  Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies.

Authors:  Matthew R Gardner; Ina Fetzer; Lisa M Kattenhorn; Meredith E Davis-Gardner; Amber S Zhou; Barnett Alfant; Jesse A Weber; Hema R Kondur; Jose M Martinez-Navio; Sebastian P Fuchs; Ronald C Desrosiers; Guangping Gao; Jeffrey D Lifson; Michael Farzan
Journal:  Mol Ther       Date:  2019-01-12       Impact factor: 11.454
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.